Skip to main content
Erschienen in: Clinical Rheumatology 12/2014

01.12.2014 | Original Article

Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers

verfasst von: Fatma Alibaz-Oner, Gonca Mumcu, Zeynep Kubilay, Gulsen Ozen, Gulce Celik, Aslı Karadeniz, Meryem Can, Sibel Yilmaz Oner, Nevsun Inanc, Pamir Atagunduz, Tulin Ergun, Haner Direskeneli

Erschienen in: Clinical Rheumatology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The clinical course of Behcet’s disease (BD) as a multisystemic disorder with a remitting-relapsing nature is insufficiently explored. As complete remission should be aimed in all inflammatory diseases, we investigated the frequency of complete remission in patients with BD followed in long-term, routine practice. In this retrospective study, 258 patients with BD who were regularly followed in outpatient clinics were assessed. The demographic and clinical data for active organ manifestations and treatment protocols were evaluated, and “complete remission” for this study was defined as no sign of any disease manifestation in the current visit and the preceding month. Two hundred fifty-eight patients with BD (F/M 130/128, mean age 41.1 ± 11.5 years) were included to the study. Mucocutaneous disease was present in 48.4 % (n = 125). Mean visit number was 6.8 ± 2.7, and mean follow-up duration was 45.8 ± 36.5 months. Patients were clinically active in 67.2 % (n = 1,182) of the total visits (n = 1,757), which increased to 75.6 % (68.1–90.3) when the month preceding the visit was also included. The most common active manifestation was oral ulcers (39.4–63.2 %) followed by other mucocutaneous manifestations and musculoskeletal involvement. When multivariate analysis was performed, oral ulcers, which are the main cause of the clinical activity, negatively correlated with immunosuppressive treatments (β = −0.356, p < 0.000) and age (β = −0.183, p = 0.04). It is fairly difficult to achieve complete remission in BD with current therapeutic regimens. The reluctance of the clinician to be aggressive for some BD manifestations with low morbidity, such as mucocutaneous lesions and arthritis, might be influencing the continuous, low-disease activity state, especially due to oral ulcers, in BD patients.
Literatur
1.
Zurück zum Zitat Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl 341:1284–1291CrossRef Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. N Engl 341:1284–1291CrossRef
2.
Zurück zum Zitat Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Düzgün N et al (2013) Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet 45(3):319–324. doi:10.1038/ng.2551 PubMedCrossRef Hughes T, Coit P, Adler A, Yilmaz V, Aksu K, Düzgün N et al (2013) Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet 45(3):319–324. doi:10.​1038/​ng.​2551 PubMedCrossRef
3.
Zurück zum Zitat Mumcu G, Inanc N, Yavuz S, Direskeneli H (2007) The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin Exp Rheumatol 25(4 Suppl 45):S27–S33PubMed Mumcu G, Inanc N, Yavuz S, Direskeneli H (2007) The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behçet's disease. Clin Exp Rheumatol 25(4 Suppl 45):S27–S33PubMed
5.
Zurück zum Zitat Mosca M, Boumpas DT, Bruce IN, Cervera R, Czirjak L, Dörner T et al (2012) Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 30(4 Suppl 73):S112–S115PubMed Mosca M, Boumpas DT, Bruce IN, Cervera R, Czirjak L, Dörner T et al (2012) Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol 30(4 Suppl 73):S112–S115PubMed
6.
Zurück zum Zitat Luqmani RA (2012) Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol 30(4 Suppl 73):S149–S153PubMed Luqmani RA (2012) Treat-to-target in vasculitis: is this a sensible approach? Clin Exp Rheumatol 30(4 Suppl 73):S149–S153PubMed
7.
Zurück zum Zitat Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH (2012) Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 46(5):e38–e45. doi:10.1097/MCG.0b013e3182431d56 PubMedCrossRef Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH (2012) Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol 46(5):e38–e45. doi:10.​1097/​MCG.​0b013e3182431d56​ PubMedCrossRef
8.
Zurück zum Zitat Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M (2011) Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S58–S63PubMed Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M, Iwaki M, Zako M (2011) Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Clin Exp Rheumatol 29(4 Suppl 67):S58–S63PubMed
9.
Zurück zum Zitat Adler S, Baumgartner I, Villiger PM (2012) Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 64(4):607–611. doi:10.1002/acr.21557 CrossRef Adler S, Baumgartner I, Villiger PM (2012) Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 64(4):607–611. doi:10.​1002/​acr.​21557 CrossRef
10.
Zurück zum Zitat Pipitone N, Olivieri I, Padula A, D’angelo S, Nigro A, Zuccoli G et al (2008) Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 59(2):285–290. doi:10.1002/art.23345 PubMedCrossRef Pipitone N, Olivieri I, Padula A, D’angelo S, Nigro A, Zuccoli G et al (2008) Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature. Arthritis Rheum 59(2):285–290. doi:10.​1002/​art.​23345 PubMedCrossRef
11.
Zurück zum Zitat International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
12.
Zurück zum Zitat Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Altas K, Yazici H (2004) The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 63(11):1450–1452PubMedCentralPubMedCrossRef Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Altas K, Yazici H (2004) The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis 63(11):1450–1452PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, Direskeneli H (2005) Clinical and immunological effects of azithromycin in Behçet’s disease. J Oral Pathol Med 34(1):13–16PubMedCrossRef Mumcu G, Ergun T, Elbir Y, Eksioglu-Demiralp E, Yavuz S, Atalay T, Direskeneli H (2005) Clinical and immunological effects of azithromycin in Behçet’s disease. J Oral Pathol Med 34(1):13–16PubMedCrossRef
14.
Zurück zum Zitat Cosgun S, Seyahi E, Mat C, Yazici H (2004) Female Behçet’s syndrome have more severe oral ulceration. XI. International Congress on Behçet’s Disease. Clin Exp Rheum 22:86 Cosgun S, Seyahi E, Mat C, Yazici H (2004) Female Behçet’s syndrome have more severe oral ulceration. XI. International Congress on Behçet’s Disease. Clin Exp Rheum 22:86
15.
16.
Zurück zum Zitat Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42(5):346–351PubMedCrossRef Tursen U, Gurler A, Boyvat A (2003) Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet’s disease. Int J Dermatol 42(5):346–351PubMedCrossRef
17.
Zurück zum Zitat Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U et al (2006) Oral health related quality of life is affected by disease activity in Behcet’s disease. Oral Dis 12:145–151PubMedCrossRef Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U et al (2006) Oral health related quality of life is affected by disease activity in Behcet’s disease. Oral Dis 12:145–151PubMedCrossRef
18.
Zurück zum Zitat Mumcu G, Hayran O, Ozalp DO, Inanc N, Yavuz S, Ergun T, Direskeneli H et al (2007) The assessment of oral health related quality of life by factor analysis in patients with Behcet disease and recurrent apthous stomatitis. J Oral Pathol Med 36:147–152PubMedCrossRef Mumcu G, Hayran O, Ozalp DO, Inanc N, Yavuz S, Ergun T, Direskeneli H et al (2007) The assessment of oral health related quality of life by factor analysis in patients with Behcet disease and recurrent apthous stomatitis. J Oral Pathol Med 36:147–152PubMedCrossRef
Metadaten
Titel
Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers
verfasst von
Fatma Alibaz-Oner
Gonca Mumcu
Zeynep Kubilay
Gulsen Ozen
Gulce Celik
Aslı Karadeniz
Meryem Can
Sibel Yilmaz Oner
Nevsun Inanc
Pamir Atagunduz
Tulin Ergun
Haner Direskeneli
Publikationsdatum
01.12.2014
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 12/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2585-3

Weitere Artikel der Ausgabe 12/2014

Clinical Rheumatology 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.